TapewireFind a company

person · Reporting owner

Daniell Richard

Disclosed activity across 1 company

Tapewire entity
49247
SEC CIK
0001726096

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063EVP, Europe CommercialMay 05, 2026May 07, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date May 05, 2026 · Filed May 07, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect55,755 Reported balance After 2026-05-05 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-05-05 · Sale · Disposed 30,000 · Balance 55,755

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 05, 2024 Filed Mar 7, 2024 21:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 55,226 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-027986 · ownership.xml · nonDerivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,996

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 22,576 $13.52 $305,123.67
Disclosure

SEC source: 0000950170-24-027986 · ownership.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,770

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2024 Filed Mar 7, 2024 21:20 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 22,576 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-027986 · ownership.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 81,845 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025982 · ownership.xml · derivative · entry 7

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,845

Underlying: Ordinary Shares · 81,845 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.

F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025982 · ownership.xml · derivative · entry 6

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,024

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.

F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 33,512 $13.34 $446,959.60
Disclosure

SEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 4

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,770

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,282

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2024 Filed Mar 5, 2024 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 62,250 $13.34 $830,246.93
Disclosure

SEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,770

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 62,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-025982 · ownership.xml · derivative · entry 5

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,753

Underlying: Ordinary Shares · 62,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027.

F5 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 62,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-025982 · ownership.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:43 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 20,599 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-023522 · ownership.xml · derivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 20,599 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vested on February 28, 2024.

F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vested on February 28, 2024.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:43 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 20,599 $13.12 $270,176.48
Disclosure

SEC source: 0000950170-24-023522 · ownership.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,770

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 to $13.19, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2024 Filed Mar 1, 2024 11:43 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 20,599 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-023522 · ownership.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,369

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
January 30, 2024 Filed Feb 1, 2024 12:28 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 55,226 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-009616 · ownership.xml · derivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,226

Underlying: Ordinary Shares · 55,226 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 07, 2023 Filed Mar 8, 2023 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 54,007 $9.43 $509,172.60
Disclosure

SEC source: 0001209191-23-017154 · doc4.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,770

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.37 to $9.725, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 18,002 $9.93 $178,776.06
Disclosure

SEC source: 0001209191-23-017154 · doc4.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,777

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $10.045, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 22,576 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 7

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,152

Underlying: Ordinary Shares · 22,576 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022 and March 5, 2023, and 22,576 vesting on each of March 5, 2024 and March 5, 2025.

F6 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vested on each of March 5, 2022 and March 5, 2023, and 22,576 vesting on each of March 5, 2024 and March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2023 Filed Mar 7, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 22,576 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016686 · doc4.xml · nonDerivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 33,512 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 6

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,536

Underlying: Ordinary Shares · 33,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.

F5 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 15,921 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 5

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 15,921 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023.

F4 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vested on each of March 4, 2021 and March 4, 2022, and 15,921 vested on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 33,512 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016686 · doc4.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,203

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2023 Filed Mar 7, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 15,921 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016686 · doc4.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,691

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 03, 2023 Filed Mar 7, 2023 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 249,003 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016686 · doc4.xml · derivative · entry 4

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,003

Underlying: Ordinary Shares · 249,003 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027.

F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 50,242 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-014435 · doc4.xml · derivative · entry 6

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 50,242 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.

F7 · derivative.expiration_date: Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 20,598 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-014435 · doc4.xml · derivative · entry 5

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,599

Underlying: Ordinary Shares · 20,598 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vesting on February 28, 2024.

F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 20,598 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023, and 20,599 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 23,654 $9.89 $233,857.64
Disclosure

SEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 4

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,770

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 50,242 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,424

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 20,598 $9.89 $203,644.19
Disclosure

SEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,182

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $9.94, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2023 Filed Mar 2, 2023 12:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 20,598 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-014435 · doc4.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,780

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 07, 2023 Filed Feb 9, 2023 12:01 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 50,242 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-007949 · doc4.xml · derivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,242

Underlying: Ordinary Shares · 50,242 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 22,576 $7.37 $166,310.62
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 6

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,182

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 22,576 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 10

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,728

Underlying: Ordinary Shares · 22,576 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 having vested on March 5, 2022 and 22,576 vesting on each of March 5, 2023, March 5, 2024 and March 5, 2025.

F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 having vested on March 5, 2022 and 22,576 vesting on each of March 5, 2023, March 5, 2024 and March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 22,576 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 5

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,758

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 134,048 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 9

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,048

Underlying: Ordinary Shares · 134,048 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 43,358 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 8

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 43,358 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F8 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F8 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 15,920 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · derivative · entry 7

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,921

Underlying: Ordinary Shares · 15,920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022, and 15,921 vesting on March 4, 2023.

F7 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022, and 15,921 vesting on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 20,456 $7.48 $153,062.02
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 4

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,182

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 43,358 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 15,920 $7.48 $119,121.40
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,280

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 15,920 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017034 · doc4.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:41 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 20,598 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-014466 · doc4.xml · derivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,197

Underlying: Ordinary Shares · 20,598 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 20,598 having vested on each of February 28, 2021 and February 28, 2022, 20,598 vesting on February 28, 2023, and 20,599 vesting on February 28, 2024.

F5 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 20,598 having vested on each of February 28, 2021 and February 28, 2022, 20,598 vesting on February 28, 2023, and 20,599 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:41 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 20,598 $8.14 $167,713.04
Disclosure

SEC source: 0001209191-22-014466 · doc4.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,280

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:41 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 20,598 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-014466 · doc4.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 13,135 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-008409 · doc4.xml · derivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 13,135 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 13,135 $9.06 $119,009.67
Disclosure

SEC source: 0001209191-22-008409 · doc4.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,280

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 13,135 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-008409 · doc4.xml · nonDerivative · entry 1

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,415

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 08, 2022 Filed Feb 10, 2022 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 43,358 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-008409 · doc4.xml · derivative · entry 4

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,358

Underlying: Ordinary Shares · 43,358 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.

F6 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 90,304 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018508 · doc4.xml · derivative · entry 4

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,304

Underlying: Ordinary Shares · 90,304 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025.

F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 22,576 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 15,920 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018508 · doc4.xml · derivative · entry 3

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,841

Underlying: Ordinary Shares · 15,920 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023.

F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:02 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 7,513 $10.58 $79,520.60
Disclosure

SEC source: 0001209191-21-018508 · doc4.xml · nonDerivative · entry 2

Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,280

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.